For research use only. Not for therapeutic Use.
XJB-5-131 is a mitochondria-targeted ROS and electron scavenger[1]. XJB-5-131 is a bi-functional antioxidant that comprises a radical scavenger. XJB-5-131 is a synthetic antioxidant that targets mitochondria[2]. XJB-5-131 is an effective ionizing irradiation protector and mitigator of cord blood mononuclear cells (CB MNCs)[3].
XJB-5-131 also ameliorates hemorrhagic shock (HS)-induced activation of the pro-apoptotic enzymes, caspases 3 and 7, in ileal mucosa[1].
XJB-5-131 reduces apoptosis and enhances cell survival in mouse embryonic cells in vitro[2].
XJB-5-131 is a radiation protector for colony-forming unit-granulocyte macrophage (CFU-GM). XJB-5-131 is an effective mitigator when added after irradiation[3].
XJB-5-131 ameliorates peroxidation of the mitochondrial phospholipid, cardiolipin, in ileal mucosal samples from rats subjected to hemorrhagic shock (HS) [1].
Intravenous treatment with XJB-5-131 (2 μmol/kg) significantly prolongs the survival of rats subjected to profound blood loss (33.5 mL/kg) despite administration of only a minimal volume of crystalloid solution (2.8 mL/kg) and the absence of blood transfusion[1].
XJB-5-131 reduces oxidative damage to mitochondrial DNA, maintains mitochondrial DNA copy number, suppresses motor decline and weight loss, enhances neuronal survival, and improves mitochondrial function. XJB-5-131 significantly suppresses the disease phenotypes and improves mitochondrial function in a mouse model of Huntington’s disease (HD) [2].
XJB-5-131 (1 mg/kg; intraperitoneally injected; three times a week up to 57 weeks) suppresses decline of weight loss and motor function in a mouse model of HD[2].
| Catalog Number | I038429 |
| CAS Number | 866404-31-1 |
| Synonyms | tert-butyl N-[(E,4S,7S)-7-benzyl-8-[(2S)-2-[[(2S)-1-[[(2S)-1-[(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)amino]-1-oxo-5-(phenylmethoxycarbonylamino)pentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-methyl-8-oxooct-5-en-4-yl]carbamate |
| Molecular Formula | C53H81N7O9 |
| Purity | ≥95% |
| InChI | InChI=1S/C53H81N7O9/c1-35(2)30-40(56-50(66)69-51(5,6)7)27-26-39(31-37-20-14-12-15-21-37)48(64)59-29-19-25-43(59)46(62)58-44(36(3)4)47(63)57-42(24-18-28-54-49(65)68-34-38-22-16-13-17-23-38)45(61)55-41-32-52(8,9)60(67)53(10,11)33-41/h12-17,20-23,26-27,35-36,39-44,67H,18-19,24-25,28-34H2,1-11H3,(H,54,65)(H,55,61)(H,56,66)(H,57,63)(H,58,62)/b27-26+/t39-,40-,42+,43+,44+/m1/s1 |
| InChIKey | VTYPGEHUYSBZTQ-VQPCLXHQSA-N |
| SMILES | CC(C)CC(C=CC(CC1=CC=CC=C1)C(=O)N2CCCC2C(=O)NC(C(C)C)C(=O)NC(CCCNC(=O)OCC3=CC=CC=C3)C(=O)NC4CC(N(C(C4)(C)C)O)(C)C)NC(=O)OC(C)(C)C |
| Reference | [1]. Carlos A Macias, et al. Treatment with a novel hemigramicidin-TEMPO conjugate prolongs survival in a rat model of lethal hemorrhagic shock. Ann Surg. 2007 Feb;245(2):305-14. [2]. Zhiyin Xun, et al. Targeting of XJB-5-131 to mitochondria suppresses oxidative DNA damage and motor decline in a mouse model of Huntington’s disease. Cell Rep. 2012 Nov 29;2(5):1137-42. [3]. Julie P Goff, et al. Evaluation of potential ionizing irradiation protectors and mitigators using clonogenic survival of human umbilical cord blood hematopoietic progenitor cells. Exp Hematol. 2013 Nov;41(11):957-66. |
